-
Roth Capital Reiterates Buy on Rexahn Pharma (RNN) as Data Flows Begin
-
Rexahn Pharma (RNN) Starts Data Flow on RX-5902, RX-3117; Roth Capital Affirms at 'Buy'
-
Roth Capital Positive on Rexahn Pharma (RNN) Following Q2 Report; Upcoming Supinoxin, RX-3117 Phase 1 Data is Key
-
Rexahn (RNN) Valuation Remains Compelling at Supinoxin, RX-3117 Phase 1 Milestones Near - Roth Capital
-
Rexahn Pharmaceuticals Reports First Quarter 2015 Financial Results and Pipeline Update
-
Roth Affirms Rexahn (RNN) at 'Buy' Following FY14 Results; Supinoxin, RX-3117 Remain in Focus
-
Rexahn Pharma (RNN) Reports Wider Loss for 2014; Updates on Clinical Development Programs
-
Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Pipeline Update
-
Roth 'Encouraged' by Rexahn's (RNN) RX-3117 Receiving FDA Orphan Drug Designation; Offers Commentary
-
Roth Affirms Rexahn (RNN) at 'Buy'; Comments on Q2 Results, Pipeline Update
-
Roth Encouraged by Progress with Supinoxin; Maintains 'Buy Rating on Rexahn Pharma (RNN)
-
Roth Affirms Rexahn (RNN) at 'Buy'; Things Shaping Up for Solid Second-Half 2014
-
Stronger-than-Expected FY13 Results Set Rexahn Pharma (RNN) Up for Promising FY14 - Analyst
-
Rexahn Pharma (RNN) Rises Back Above $1 Level with Volume
-
Rexahn Pharma (RNN) Announces $20M Registered Direct Offering
-
Notable 52-Week Highs and Lows of the Day 01/09: (RNN) (M) (WAG) High; (MRGE) (LULU) Low
-
Roth Capital Starts Rexahn Pharma (RNN) at Buy; Pieces in Place for Ground-Floor Opportunity
-
Notable Analyst Rating Changes 01/09: (JCP) (M) (AET) Upgraded; (BWLD) (S) (NVDA) Downgraded
-
Pre-Open Stock Movers 1/9: (ICPT) (CRDC) (F) Higher; (YRCW) (FDO) (PIR) Lower (more...)
-
Roth Capital Starts Rexahn Pharmaceuticals Inc. (RNN) at Buy

